GLIMEPIRIDE\METFORMIN: 73 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
73
Total FAERS Reports
4 (5.5%)
Deaths Reported
19
Hospitalizations
73
As Primary/Secondary Suspect
4
Life-Threatening
3
Disabilities
First Report: 2007 · Latest Report: 20240101
What Are the Most Common GLIMEPIRIDE\METFORMIN Side Effects?
#1 Most Reported
Hyperglycaemia
9 reports (12.3%)
#2 Most Reported
Vision blurred
8 reports (11.0%)
#3 Most Reported
Hypoglycaemia
8 reports (11.0%)
All GLIMEPIRIDE\METFORMIN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Hyperglycaemia | 9 | 12.3% | 0 | 3 |
| Hypoglycaemia | 8 | 11.0% | 0 | 3 |
| Vision blurred | 8 | 11.0% | 3 | 2 |
| Product prescribing error | 7 | 9.6% | 0 | 1 |
| Blood glucose increased | 6 | 8.2% | 0 | 1 |
| Diarrhoea | 6 | 8.2% | 0 | 1 |
| Drug ineffective | 6 | 8.2% | 0 | 1 |
| Weight increased | 6 | 8.2% | 2 | 0 |
| Asthenia | 5 | 6.9% | 0 | 1 |
| Diabetes mellitus | 5 | 6.9% | 0 | 1 |
| Incorrect dose administered | 5 | 6.9% | 0 | 0 |
Who Reports GLIMEPIRIDE\METFORMIN Side Effects? Age & Gender Data
Gender: 64.3% female, 35.7% male. Average age: 60.1 years. Most reports from: BR. View detailed demographics →
Is GLIMEPIRIDE\METFORMIN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2007 | 1 | 0 | 0 |
| 2009 | 5 | 0 | 3 |
| 2012 | 5 | 0 | 3 |
| 2013 | 3 | 1 | 1 |
| 2014 | 4 | 0 | 2 |
| 2015 | 2 | 0 | 0 |
| 2016 | 3 | 0 | 0 |
| 2017 | 2 | 0 | 1 |
| 2018 | 3 | 0 | 0 |
| 2019 | 3 | 0 | 0 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 0 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 0 |
| 2024 | 1 | 0 | 0 |
What Is GLIMEPIRIDE\METFORMIN Used For?
| Indication | Reports |
|---|---|
| Diabetes mellitus | 22 |
| Type 2 diabetes mellitus | 12 |
| Product used for unknown indication | 11 |
Official FDA Label for GLIMEPIRIDE\METFORMIN
Official prescribing information from the FDA-approved drug label.